Sign In
Buy GTHX
$7.15
+0 (+0%)
At Close: Dec 16, 2024
G1 Therapeutics to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day Virtual Conference
07:30am, Thursday, 04'th Feb 2021
RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey w
Glancy Prongay & Murray LLP Announces Investigation of G1 Therapeutics, Inc.
03:22pm, Tuesday, 26'th Jan 2021
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors' and officers' possible
G1 Therapeutics Likely Still Has Long-Term Upside Ahead Of The Trilaciclib PDUFA Date
11:28am, Monday, 18'th Jan 2021
G1 Therapeutics has a PDUFA date coming up on February 15, 2021 for its first therapy, trilaciclib in SCLC. G1's stock has moved hugely upward over the last few months as investors begin to anticipate
G1 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021
07:00am, Tuesday, 05'th Jan 2021
RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will p
G1 Therapeutics Announces Appointment of William C. Roberts as Vice President, Investor Relations & Corporate Communications
07:00am, Monday, 04'th Jan 2021
- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) -
Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer Company also presents updated monotherapy
G1 Therapeutics: Depressed Price Before Catalyst, No Apparent Reason
05:28am, Friday, 27'th Nov 2020
GTHX stock is depressed but I don't see any reason. PDUFA of Feb. 15, 2021, is a major catalyst.
G1 Therapeutics to Present Clinical Data on Trilaciclib and Rintodestrant at 2020 San Antonio Breast Cancer Symposium (SABCS)
07:00am, Wednesday, 18'th Nov 2020
RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its
G1 Therapeutics to Present at the Stifel Virtual Healthcare Conference on November 18, 2020
07:01am, Wednesday, 11'th Nov 2020
RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will p
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2020 Results - Earnings Call Transcript
09:31pm, Wednesday, 04'th Nov 2020
G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2020 Results - Earnings Call Transcript
G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020
07:01am, Wednesday, 28'th Oct 2020
RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call
G1 Therapeutics: Buy, Sell Or Hold
04:27pm, Sunday, 30'th Aug 2020
Today, we take an in-depth look at G1 Therapeutics. This small oncology concern out of North Carolina has a couple of shots on goal, potential catalysts on the horizon and is well funded.
Oncology Stocks Area Trading Materially Lower The Last 2 Months
08:00am, Monday, 24'th Aug 2020
Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.
G1 Therapeutics' NDA Accepted, And Other News: The Alpha And Omega Of Biopharma
12:41am, Thursday, 20'th Aug 2020
G1 Therapeutics receives FDA acceptance of its Small Cell Lung Cancer NDA. Gilead suffers setback on filgotinib NDA front.
G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer
10:00am, Monday, 17'th Aug 2020
\- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration \- Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robu
